Immunocompromised Host
12 cases on infection risk and prophylaxis in non-HIV immunocompromising conditions and therapies — targeted biologics, transplant immunosuppression, complement inhibition, splenectomy, and primary immunodeficiency — choose a case below to open its full multi-voice debate.
Nine days into AML induction therapy, a neutropenic fever arrives in a patient whose gut is colonized with a resistant organism the standard first-line antibiotic cannot reliably reach — testing how far a guideline default should bend to fit one patient's own known flora.
A new PNH diagnosis with an active clot forces a decision about starting a complement inhibitor before the labeled two-week meningococcal vaccination window has passed.
Starting a BTK inhibitor for CLL raises real invasive fungal risk, and the antifungal that addresses it interacts directly with the drug being protected against.
A BCMA-directed bispecific antibody for multiple myeloma has driven this patient's IgG far lower than her prior anti-CD20 therapy ever did, testing whether replacement should wait for the next infection or start at the number itself.
A treated rejection episode raises the question of whether a kidney transplant recipient's completed prophylaxis courses should restart, even though his transplant date says they shouldn't need to.
Three years of a trough that once counted as adequate hasn't stopped two pneumonias and new bronchiectasis, testing whether the old IVIG target itself was ever right for this patient specifically.
A vision-threatening flare of giant cell arteritis needs immediate high-dose steroids in a patient whose decades in a strongyloides-endemic region make that same treatment dangerous without care taken in the same visit.
A rapid-onset sepsis in a patient whose post-splenectomy prophylaxis quietly lapsed years ago raises both an urgent empiric-antibiotic question and a genuinely unsettled one about how long that prophylaxis should have continued.
A rheumatoid arthritis flare needs a JAK inhibitor now, in a patient whose zoster history and drug class both raise real reactivation risk before a two-dose vaccine series can finish.
Six infection-free years into adulthood, a patient with X-linked chronic granulomatous disease asks whether the interferon-gamma injections that shaped his childhood are still doing the work he's always assumed they were.
A varicella-susceptible patient with steroid-refractory Crohn's disease needs an urgent biologic his disease cannot wait for, in a window too short for the vaccine that would normally come first.
Three years into chronic graft-versus-host disease, a trimodal prophylaxis regimen started without an end date meets its first real reassessment against the cumulative cost of staying on it.